CURE.X — Biocure Technology Income Statement

0.000.00%

Last trade - 00:00

EnergyHighly SpeculativeMicro CapValue Trap

Annual income statement for Biocure Technology, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	R2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Total Revenue	0	0	0	0	0
Cost of Revenue
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	4.73	3.12	1.86	0.408	0.674
Operating Profit	-4.73	-3.12	-1.86	-0.408	-0.674
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-4.79	-3.08	-1.87	-0.403	-1.49
Net Income After Taxes	-4.79	-3.08	-1.87	-0.403	-1.49
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-4.74	-2.95	-1.13	-1.45	-1.81
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-4.74	-2.95	-1.13	-1.45	-1.81
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.44	-0.289	-0.162	-0.053	-0.113